The FDA Guidance released in 2008 offers industry insight to why evaluation of heart risk in clinical trials is necessary. ICE E-14 Step 2 Guidance for Industry Integrated Cardiovascular Safety Early Accuracy in New Drug Safety Analysis Cardiac Safety: The Merits of ECG Centralization